---
schema_version: "secwatch.filing_event.v1"
accession: "0001703057-26-000003"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2026-01-14T23:59:59+00:00"
generated_at: "2026-05-16T10:25:18.993685+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# AbCellera doses first patients in Phase 2 trial of ABCL635 for menopausal vasomotor symptoms

## Summary
- ABCL635, a non-hormonal candidate for moderate-to-severe vasomotor symptoms (VMS) of menopause, advances to Phase 2.
- Phase 2 is a randomized, double-blind, placebo-controlled study in 80 postmenopausal women.
- Top-line clinical results for both Phase 1 and Phase 2 expected in Q3 2026.
- Phase 1/2 redesignation based on interim safety, tolerability, and pharmacodynamic data from healthy volunteers.

## SEC filing metadata
- accession: 0001703057-26-000003
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2026-01-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000003/0001703057-26-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000003/abcl-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001703057-26-000003
- JSON: https://secwatch.observer/filing/0001703057-26-000003.json
- Plain text: https://secwatch.observer/filing/0001703057-26-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.